Denali Secures FDA Nod for First Brain-Penetrant Hunter Syndrome Therapy in Two Decades
Event summary
- Denali's AVLAYAH (tividenofusp alfa-eknm) received FDA accelerated approval for treating neurologic manifestations of Hunter syndrome (MPS II) on March 25, 2026.
- The approval is based on a 91% reduction in cerebrospinal fluid heparan sulfate (CSF HS) levels in a Phase 1/2 trial.
- AVLAYAH is the first FDA-approved therapy designed to cross the blood-brain barrier using Denali's TransportVehicle™ platform.
- Denali received a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the approval.
The big picture
Denali's FDA approval marks a significant milestone in the treatment of Hunter syndrome, addressing a critical unmet need for therapies that can penetrate the blood-brain barrier. The approval validates Denali's TransportVehicle™ platform, positioning the company as a leader in developing biotherapeutics for central nervous system diseases. The Rare Pediatric Disease Priority Review Voucher adds strategic value, potentially accelerating future regulatory reviews for Denali or other sponsors.
What we're watching
- Clinical Validation
- Whether the ongoing Phase 2/3 COMPASS study will confirm AVLAYAH's clinical benefit and support global regulatory approvals.
- Market Penetration
- The pace at which Denali can commercialize AVLAYAH and capture market share in the Hunter syndrome treatment space.
- Platform Potential
- How Denali's TransportVehicle™ platform will be leveraged for other neurodegenerative diseases and lysosomal storage disorders.
Related topics